Lista de obras -

A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors

artículo científico publicado en 2013

A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma

artículo científico publicado en 2014

A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer

artículo científico publicado en 2011

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

artículo científico publicado en 2012

Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification

artículo científico publicado en 2011

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

artículo científico publicado en 2010

Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma

artículo científico publicado en 2014

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.

artículo científico publicado en 2015

Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

artículo científico publicado en 2010

Delaying chemoradiation until after completion of adjuvant chemotherapy for pancreatic cancer may not impact local control

artículo científico publicado en 2013

Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy

artículo científico publicado en 2010

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

artículo científico publicado en 2011

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study

artículo científico publicado en 2009

Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas

artículo científico publicado en 2006

FOLFIRINOX in Locally Advanced Pancreatic Cancer: The Massachusetts General Hospital Cancer Center Experience ⬇️

artículo científico publicado el 8 de mayo de 2013

Familial Gastric Cancers

artículo científico publicado en 2015

First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer.

artículo científico publicado en 2015

Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping ⬇️

artículo científico publicado el 16 de diciembre de 2011

Hereditary colorectal cancer syndromes: an overview

artículo científico publicado en 2007

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

artículo científico publicado en 2005

Isolation of rare circulating tumour cells in cancer patients by microchip technology

artículo científico publicado en 2007

Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose-painted IMRT per RTOG 0529

artículo científico

MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib

artículo científico publicado en 2011

Mammary tumorigenesis following transgenic expression of a dominant negative CHK2 mutant

artículo científico publicado en 2006

Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma

artículo científico publicado en 2015

Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer

artículo científico publicado en 2013

Mutational analysis and clinical correlation of metastatic colorectal cancer

artículo científico publicado en 2014

Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer

artículo científico publicado en 2014

NCCN Task Force Report: mTOR inhibition in solid tumors.

artículo científico publicado en 2008

Phase 1/2 study of everolimus in advanced hepatocellular carcinoma

artículo científico publicado en 2011

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors ⬇️

artículo científico publicado el 3 de diciembre de 2010

Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors ⬇️

artículo científico publicado el 23 de abril de 2012

Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.

artículo científico publicado en 2015

Preoperative Cetuximab, Irinotecan, Cisplatin, and Radiation Therapy for Patients With Locally Advanced Esophageal Cancer ⬇️

artículo científico publicado el 21 de febrero de 2013

Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma

artículo científico publicado en 2015

ROS1 rearrangements define a unique molecular class of lung cancers

artículo científico publicado en 2012

Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer

artículo científico publicado en 2015

Rapid Radiographic and Clinical Improvement After Treatment of a MET-Amplified Recurrent Glioblastoma With a Mesenchymal-Epithelial Transition Inhibitor ⬇️

artículo científico publicado el 12 de diciembre de 2011

Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer

artículo científico publicado en 2010

Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor

artículo científico publicado en 2015

Targeted agents: the rules of combination

artículo científico publicado en 2007

Targeted therapies with chemoradiation in esophageal cancer: development and future directions

artículo científico

Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer

artículo científico publicado en 2015

Updated long-term outcomes and prognostic factors for patients with unresectable locally advanced pancreatic cancer treated with intraoperative radiotherapy at the Massachusetts General Hospital, 1978 to 2010

artículo científico publicado en 2013

Lista de obras de

A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors

A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma

A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.

Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

Delaying chemoradiation until after completion of adjuvant chemotherapy for pancreatic cancer may not impact local control

Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study

Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas

FOLFIRINOX in Locally Advanced Pancreatic Cancer: The Massachusetts General Hospital Cancer Center Experience ⬇️

Familial Gastric Cancers

First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer.

Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping ⬇️

Hereditary colorectal cancer syndromes: an overview

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

Isolation of rare circulating tumour cells in cancer patients by microchip technology

Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose-painted IMRT per RTOG 0529

MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib

Mammary tumorigenesis following transgenic expression of a dominant negative CHK2 mutant

Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma

Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer

Mutational analysis and clinical correlation of metastatic colorectal cancer

Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer

NCCN Task Force Report: mTOR inhibition in solid tumors.

Phase 1/2 study of everolimus in advanced hepatocellular carcinoma

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors ⬇️

Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors ⬇️

Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.

Preoperative Cetuximab, Irinotecan, Cisplatin, and Radiation Therapy for Patients With Locally Advanced Esophageal Cancer ⬇️

Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma

ROS1 rearrangements define a unique molecular class of lung cancers

Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer

Rapid Radiographic and Clinical Improvement After Treatment of a MET-Amplified Recurrent Glioblastoma With a Mesenchymal-Epithelial Transition Inhibitor ⬇️

Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer

Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor

Targeted agents: the rules of combination

Targeted therapies with chemoradiation in esophageal cancer: development and future directions

Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer

Updated long-term outcomes and prognostic factors for patients with unresectable locally advanced pancreatic cancer treated with intraoperative radiotherapy at the Massachusetts General Hospital, 1978 to 2010